JP2012512147A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512147A5
JP2012512147A5 JP2011540134A JP2011540134A JP2012512147A5 JP 2012512147 A5 JP2012512147 A5 JP 2012512147A5 JP 2011540134 A JP2011540134 A JP 2011540134A JP 2011540134 A JP2011540134 A JP 2011540134A JP 2012512147 A5 JP2012512147 A5 JP 2012512147A5
Authority
JP
Japan
Prior art keywords
preparation according
depot preparation
depot
polymer
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011540134A
Other languages
English (en)
Japanese (ja)
Other versions
JP5721635B2 (ja
JP2012512147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/067049 external-priority patent/WO2010079047A2/en
Publication of JP2012512147A publication Critical patent/JP2012512147A/ja
Publication of JP2012512147A5 publication Critical patent/JP2012512147A5/ja
Application granted granted Critical
Publication of JP5721635B2 publication Critical patent/JP5721635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011540134A 2008-12-15 2009-12-14 一定して高い曝露レベルを有するオクトレオチドのデポー製剤 Active JP5721635B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08171712 2008-12-15
EP08171712.6 2008-12-15
PCT/EP2009/067049 WO2010079047A2 (en) 2008-12-15 2009-12-14 Octreotide depot formulation with constantly high exposure levels

Publications (3)

Publication Number Publication Date
JP2012512147A JP2012512147A (ja) 2012-05-31
JP2012512147A5 true JP2012512147A5 (https=) 2013-02-07
JP5721635B2 JP5721635B2 (ja) 2015-05-20

Family

ID=40520410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540134A Active JP5721635B2 (ja) 2008-12-15 2009-12-14 一定して高い曝露レベルを有するオクトレオチドのデポー製剤

Country Status (25)

Country Link
US (10) US20100151033A1 (https=)
EP (1) EP2376070B1 (https=)
JP (1) JP5721635B2 (https=)
KR (1) KR101708517B1 (https=)
CN (3) CN105233251A (https=)
AR (1) AR074603A1 (https=)
AU (1) AU2009336718B9 (https=)
BR (1) BRPI0922607B1 (https=)
CA (1) CA2746968C (https=)
CL (1) CL2011001438A1 (https=)
CO (1) CO6382109A2 (https=)
EC (1) ECSP11011199A (https=)
ES (1) ES2602614T3 (https=)
IL (1) IL213034A (https=)
MA (1) MA32964B1 (https=)
MX (1) MX2011006335A (https=)
MY (1) MY159789A (https=)
NZ (1) NZ592998A (https=)
PE (1) PE20110876A1 (https=)
PL (1) PL2376070T3 (https=)
PT (1) PT2376070T (https=)
RU (1) RU2526822C2 (https=)
SG (1) SG171255A1 (https=)
TN (1) TN2011000261A1 (https=)
WO (1) WO2010079047A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
EP2851085B1 (en) * 2012-05-14 2019-06-26 Teijin Limited Protein ccomposition sterilized by radiation
JP6494657B2 (ja) * 2014-03-31 2019-04-03 ファーマシェン エス．エー． 徐放特性を持つペプチド充填ｐｌｇａミクロスフェアの調製
WO2016094662A1 (en) 2014-12-10 2016-06-16 Chiasma Inc. Oral octreotide administered in combination with other therapeutic agents
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
EP3681469A1 (en) * 2017-09-15 2020-07-22 Oxular Limited Ophthalmic drug compositions
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
GB9513224D0 (en) * 1995-06-29 1995-09-06 Sandoz Ltd Organic compounds
ATE418323T1 (de) * 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
CA2631811C (en) * 2005-12-22 2017-06-20 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Similar Documents

Publication Publication Date Title
JP2012512147A5 (https=)
JP2015044823A5 (https=)
ES2385384T3 (es) Formulación de fármaco de moléculas pequeñas de liberación prolongada
CN103002917B (zh) 可注射长效抗精神病组合物
KR101930588B1 (ko) 마이크로입자 중에 소마토스타틴 유도체를 포함하는 연장-방출 조성물
CN102580111B (zh) 槲皮素羟丙基β-环糊精包和物脂质体及其制备方法和用途
JP2013177406A5 (https=)
RU2008129626A (ru) Композиции с замедленным высвобождением, включающие октреотид и два или более сополимера полилактида и глюколида
RU2011128538A (ru) Содежащий октреотид состав с замедленным высвобождением со стабильно высоким уровнем воздействия
KR100633280B1 (ko) 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법
RU2010135629A (ru) Репаративная форма с замедленным высвобождением, содержащая октреотид и три линейных полимера поли(лактид-со-гликолида)
CN1901905A (zh) 鼻内用组合物
CN111603439B (zh) 一种长效依匹哌唑原位相变凝胶注射剂及其制备方法
CN1969818A (zh) 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN101721370A (zh) 戈舍瑞林缓释微球制剂及其制备方法、检测方法
CN101511341A (zh) 芳香酶抑制剂的缓释制剂
CN103908659B (zh) Lhrh类似物和齐考诺肽组合物缓释微球制剂及其制备方法
CN101219113A (zh) 含苯达莫司汀的复方抗癌缓释注射剂
CN101130057B (zh) 胸腺五肽长效植入剂及其制备方法
CN101380292A (zh) 一种缓释注射剂及其制备方法和应用
CN105497880A (zh) 治疗骨质疏松的药物组合物缓释微球制剂及其制备方法
CN112451475B (zh) 一种用于治疗空洞型肺结核的长效缓释凝胶
CN101219112A (zh) 一种含苯达莫司汀的复方抗癌缓释注射剂
CN100998555A (zh) 一种含血管抑制剂的抗癌缓释剂
CN1187047C (zh) 地非三唑在制备治疗恶性肿瘤疾病药剂中的应用